Peptide Sciences
This is one entry from the TitrateLab Vendor Graveyard, a dated, primary-source archive of peptide-market shutdowns, exit scams, and enforcement actions. Documented as March 6, 2026. Sources for this entry are named inline below and numbered in full on the parent archive page.
The largest single loss of grey-market capacity in the market’s history.
Peptide Sciences (Henderson, Nevada) posted a three-sentence notice on March 6, 2026 announcing voluntary shutdown: “After careful consideration, Peptide Sciences has made the decision to voluntarily shut down operations and discontinue the sale of our research products.” No refund process was announced. Pending orders became losses.
Peptide Sciences had been the largest grey-market research-peptide vendor in the United States. $7.4 million in online sales in December 2025 alone (per Grips Intelligence). The company had operated for 10+ years.
The shutdown came 8 days after Secretary Kennedy’s Feb 27 JRE announcement that the FDA was moving ~14 peptides back to Category 1. The read in community channels was straightforward: with compounded alternatives returning and DOJ already mid-prosecution against peer vendors, Peptide Sciences’ founders had nothing left to defend. Staying open meant being the next headline. They closed instead.
Why it still matters: End of the 2020–2025 “bulletproof grey market” era. Customer migration drove measurable spikes at Limitless Biotech, Prime Peptides, and smaller vendors in the weeks after. The aftermath is still unfolding as of this writing.
Primary sources: contemporaneous Twitter/X announcement capture; Lumalex Law analysis; Peptide Dossier retrospective.